GlassScriptPhysician profile
Alia Abdulla
NPI 1609040039
$9,709.84
in general payments reported to CMS, 2019-2025
21 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,774 · 2020: $3,470 · 2021: $23.29 · 2022: $1,403 · 2023: $932 · 2024: $969 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,086 · Food and Beverage: $954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,086.06 |
| Food and Beverage | $954.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,483.51 | 2019-2020 | |
| Hologic INC | $996.59 | 2022-2024 | Biozorb, Localizer |
| Leica Microsystems INC. | $773.53 | 2019-2023 | |
| Endomagnetics LTD | $602.24 | 2022-2024 | Magtrace, Magseed |
| Elucent Medical | $372.96 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $275.00 | 2020-2022 | |
| Pacira Pharmaceuticals Incorporated | $231.97 | 2020 | |
| Myriad Genetic Laboratories, INC. | $156.72 | 2023-2025 | Myrisk |
| Aroa Biosurgery Incorporated | $137.98 | 2023 | |
| Ethicon US, LLC | $129.73 | 2019 | |
| Dilon Technologies, INC. | $123.88 | 2025 | Hemoblast Bellows |
| Medical Device Business Services, INC. | $108.97 | 2019 | |
| Medtronic, INC. | $98.46 | 2024 | Ligasure |
| Covidien LP | $47.20 | 2019 | |
| Shire North American Group INC | $34.67 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $29.80 | 2023 | Affirm Prone Biopsy System, Localizer, Celero-12 |
| Tela Bio, INC. | $27.58 | 2020 | |
| Allergan, INC. | $23.42 | 2020 | |
| Innocoll Pharmaceuticals Limited | $23.29 | 2021 | |
| Abbvie INC. | $17.24 | 2024 | |
| Advanced Accelerator Applications | $15.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alia Abdulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.